TY  - GEN 
AU  - Cobo, M.
AU  - Rodriguez-Abreu, D.
AU  - Parente, D. P.
AU  - Gracia, P. R.
AU  - García González, Jorge José
PY  - 2021
SN  - 2366-1070
UR  - http://hdl.handle.net/20.500.11940/18475
AB  - Atezolizumab is a monoclonal antibody targeting the programmed death ligand 1 (PD-L1) that was approved in 2017 in the USA and Europe for the second-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). This review article...
LA  - en
TI  - Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review
DO  - 10.1007/s40487-021-00139-3
KW  - CHUS
VL  - 9
ER  -